A 51-year-old female patient in the first chronic phase of CML received an allogeneic PBSCT from a matched unrelated donor. The transplant was manipulated by CD34 ؉ cell selection. On day ؉193 after transplantation the patient was readmitted to the hospital with recurrent fever of unknown origin and cough. Clinical, radiographic and sonographic evaluation revealed no characteristic findings besides a mild splenomegaly. 
EBV-LPD is a serious complication after allogeneic PBSCT or BMT and occurs in up to 25% of patients. The grade of severity ranges from post-transplant infectious mononucleosis to monoclonal B cell lymphoma with a lethal outcome in most of the cases. 1 Risk factors for the development of EBV-LPD include haploidentical transplantation or the use of a marrow from a matched unrelated donor (MUD), the grade of graft-versus-host disease (GVHD) and T cell depletion of the transplant. 2 Two strategies have been used to treat severe cases of EBV-LPD: first, the infusion of donor lymphocytes, which has been proven to be effective in several clinical trials 3, 4 and second, the application of a monoclonal CD20 antibody (rituximab) if donor lymphocytes are not available or if the interruption of immunosuppression is not feasible. 5 Successful treatment seems to be dependent upon early initiation of therapy and therefore early detection of the disease is mandatory. 6, 7 Here, we report a very atypical case of a female CML patient, who developed EBV-LPD about day ϩ190 after allogeneic PBSCT without any characteristic clinical findings and died on day ϩ204 with an uncertain diagnosis.
Case report
In May 1999, a 51-year-old woman was admitted to our hospital with elevated WBC (30 ϫ 10 9 /l) and a Phϩ CML in first chronic phase was diagnosed. The patient was treated with hydroxyurea. Because no HLA-identical siblings were available, an allogeneic peripheral blood stem cell transplant (PBSCT) from a MUD was performed in October 1999. Both the donor as well as the recipient were seropositive for EBV (donor: positive for IgG antibodies against EBV-VCA; recipient: positive for EBV-VCA-IgG antibodies (1:64); negative for EBV-VCA-IgA, EBNA and EBV-EA antibodies). The donor was CMV seronegative, the recipient seropositive. The conditioning regimen included fractionated total body irradiation in divided doses of 2 ϫ 2 Gy on days Ϫ9 to Ϫ7 (total dose 12 Gy); thiotepa 10 mg/kg once daily i.v. on day Ϫ5, cyclophosphamide 60 mg/kg once daily on days Ϫ3 and Ϫ2. Anti-thymocyteglobulin (Fresenius, Bad Homburg, Germany) 5 mg/kg i.v. once daily for 4 consecutive days starting from day Ϫ4 was administered as rejection prophylaxis. On day 0, the patient received an ex vivo CD34 positively selected transplant /l on day ϩ10 and platelets Ͼ40 ϫ 10 9 /l on day ϩ12. On day ϩ15 the patient developed GVHD grade I-II (WHO) of the skin, which was confirmed histologically. Prednisone was initiated at a dose of 150 mg per os (p.o.) per day with a rapid regression of the skin manifestations and the patient was released on day ϩ22 from the hospital after reduction of the steroid dose to 100 mg p.o. per day.
In the post-transplantation period the patient encountered two major problems (Figure 1 ). First, a severe steroid myopathy which could be controlled by substituting the steroids for CsA and second, a CMV reactivation with antigenemia and virus isolation from leukocytes (peak antigenemia: 75 antigen positive cells on day ϩ74). The infection was successfully treated with foscarnet. Restriction fragment length polymorphism (RFLP) analysis was performed three times and showed a complete donor chimerism. The patient was readmitted to the hospital on day ϩ193 with fever of unknown origin and cough. At the time of admission the patient was hematologically reconstituted with a WBC of 5.0 ϫ 10 9 /l, Hb of 9.8 g/dl and platelets of 137 ϫ 10 9 /l. Lymphocyte counts were still low, slowly recovering from T cell and B cell depletion. Clinical examination revealed no characteristic findings such as organomegaly or enlargement of peripheral lymph nodes. An X-ray and CT scan of the chest showed weak bilateral interstitial infiltrates. Thus, an atypical pneumonia or an aspergillus infection were suggested by the radiologist as differential diagnoses. Antibiotic therapy with tazobactam-piperacillin and clarithromycin was initiated and immunosuppression with CsA was continued. On day ϩ199 a bronchioalveolar lavage was performed and no fungal or bacterial agents could be isolated. The lavage was negative for CMV-antigen as assessed by immunofluorescence, however, CMV was finally isolated in long-term culture. Serological testing for EBV showed EBV-VCAIgG antibodies (1:256) and a marginal titer for EBV anti-EBNA-Ab (1:8). During the further clinical course the patient developed diarrhea with three to six stools per day and an increase of liver values (ALT maximum (max) 70 IU/l, AST max 113 IU/l, GGT max 314 IU/l, alkaline phosphatase max 658 IU/l). Stool cultures for viruses were negative. The patient had persisting fever of about 39°C. In the absence of an obvious infectious focus, our working hypothesis was switched to systemic GVHD and therapy with prednisone in a dose of 150 mg per day was reinitiated on day ϩ200. Despite antibiotic and immunosuppressive treatment, the patient's temperature rose to 40°C. Subsequently the antibiotic therapy was changed to imipenem (day ϩ202). Because of generalized seizures on the morning of day ϩ203, a cranial CT scan was performed and revealed no pathological findings. The cerebrospinal fluid (CSF) showed a pleocytosis (300/3) with atypical lymphocytes and systemic treatment with aciclovir was started. Using a short-time DNA extraction method, PCR of the CSF initially detected CMV-DNA, but no EBV-DNA. In the evening of day ϩ203 the patient again developed generalized seizures and finally respiratory insufficiency. She underwent cardiopulmonary resuscitation and was transferred to the ICU for ventilatory support. During day ϩ204 the patient developed anuria, liver insufficiency and died in multiorgan failure. The macroscopic post-mortem showed severe colitis and a mild splenomegaly but no pathological findings in heart, lung, liver and kidney. We examined specimens derived from adrenal and renal tissue, liver and brain stem with an anti-CMV antibody (1:50 monoclonal mouse anti-cytomegalovirus, Dako, Glostrup, Denmark). All samples were CMV-negative.
Unexpectedly, the histological and immunohistological examination showed a diffuse infiltration of all internal organs, including the colon wall, and additionally the brain by lymphoblastoid B cells (Figure 2 ). These lymphoblastoid cells stained positive for EBV-LMP (latent membrane protein; 1:50 monoclonal mouse antibody, clones CS 1-4, Dako). LMP-expression is indicative for EBV-related infection and transformation. 8 The final diagnosis, therefore, was EBV-LPD. Analysis of immunoglobulin heavy chain gene rearrangement revealed monoclonality (Figure 3 ).
Discussion
In view of the unusual clinical presentation of the case it is important to evaluate the evidence provided for the presence of diffuse EBV-LPD. We considered the histology, the detection of LMP on the surface of the tumor cells by immunohistology, the monoclonality of the B cells and the detection of cell-associated EBV-DNA by PCR in the cerebrospinal fluid as overwhelming and compelling evidence for EBV-LPD. We found no evidence for the presence of another infection, especially CMV.
The decisive question is: why was the right diagnosis missed in vivo? Our patient was at intermediate risk for the development of EBV-LPD: risk factors were the T celldepleted transplantation from a MUD and the occurrence of acute GVHD. 2 Our method of T cell depletion should have reduced the risk of EBV-LPD. CD34
ϩ selection eliminates donor B cells from which EBV lymphoma usually arises. B cell depletion by treating grafts with anti-CD52 or anti-CD19 monoclonal antibodies has been shown to reduce the risk of EBV-LPD. 9, 10 Clearly this conclusion is only valid if the lymphoma cells are donor-derived. This is highly likely, because all lymphocytes in the peripheral blood of the patient were shown to be donor-derived by RFLP analysis for several time points post PBSCT. Gener- ally, EBV-LPD is associated with typical clinical symptoms such as enlarged lymph nodes, hepatosplenomegaly and/or fever, as well as laboratory findings like the appearance of atypical B lymphocytes, a positive EBV-PCR or the spontaneous in vitro growth of immortalized B cells. 6, 7 Following transplantation the patient was seen regularly in our outpatient clinic. Like all patients receiving a T celldepleted graft in our center, monthly monitoring for EBVreactivation was performed by semiquantitative PCR until day ϩ180. Relevant results of the post-transplantation course are summarized together with the acute phase of illness in Figure 1 and provide no hints for EBV reactivation during the observation period. Although PCR from leukocytes is considered as the method of choice for the early detection of EBV reactivation, one should be aware of the fact that the results can be falsely negative, especially in B cell-depleted patients, due to the initially low number of circulating B cells. 11 In our case, the EBV-PCR assay should have been repeated later and especially in the acute phase of illness. The diagnostic value of EBV serology is controversial in marrow or PBSC recipients due to the impaired humoral response and the observation that many patients, who are able to produce antibodies, show serological signs of reactivated EBV infections without clinical manifestations. It is important to note that the initial EBV-PCR using an aliquot of the cerebrospinal fluid was negative. A second PCR of the same CSF after centrifugation and complete lysis of the cell pellet was performed in triplicate retrospectively and revealed a positive result with 5000 EBV copies per milliliter (CSF plus lysed cells).
Bone Marrow Transplantation
The acute phase of illness started with the readmission of the patient to our hospital on day ϩ193. All symptoms were unspecific and the diagnosis of EBV-LPD was made particularly difficult by the complete absence of any lymph node enlargement. The first working hypothesis in our patient was atypical pneumonia and was then focused on systemic GVHD, when the patients symptoms did not resolve under adequate antibiotic therapy. The syndrome of diarrhea, impairment of liver function and pulmonary symptoms was consistent with the latter diagnosis. The occurrence of pleocytosis with atypical lymphocytes in the cerebrospinal fluid of the patient 1 day prior to death was suggestive of viral encephalitis and the initiation of antiviral therapy with aciclovir was reasonable. Recent data showed the feasibility and efficacy of prophylactic infusions of EBV-specific donor-derived CTL for the prevention of EBV-LPD. 3 With this immunoprophylaxis, no manifestations of EBV-LPD were documented and even patients, who already showed greatly increased amounts of Bone Marrow Transplantation EBV-DNA at study entry, responded to therapy with a rapidly decreasing virus load and the prevention of lymphoma. Our patient would have met the inclusion criteria for this treatment because she received a T cell-depleted transplant from a MUD.
This atypical case shows the fulminant development of a diffuse form of EBV-LPD after allogeneic PBSCT without characteristic clinical findings. Furthermore these data demonstrate the importance of prolonged PCR-based monitoring for EBV in transplant patients, especially after T cell depletion. Specifically, if CSF is analyzed by PCR for EBV-DNA, cells have to be included in DNA extraction. This case also highlights the importance of the ongoing discussion about prophylactic infusions of donor-derived EBV-specific CTL for patients at risk.
